Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Current Leases: 2019-2025

Historic Current Leases for Intellia Therapeutics (NTLA) over the last 7 years, with Sep 2025 value amounting to $27.4 million.

  • Intellia Therapeutics' Current Leases rose 42.76% to $27.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $27.4 million, marking a year-over-year increase of 42.76%. This contributed to the annual value of $20.2 million for FY2024, which is 8.86% up from last year.
  • Intellia Therapeutics' Current Leases amounted to $27.4 million in Q3 2025, which was up 1.44% from $27.0 million recorded in Q2 2025.
  • In the past 5 years, Intellia Therapeutics' Current Leases ranged from a high of $38.8 million in Q1 2025 and a low of $7.4 million during Q2 2021.
  • Moreover, its 3-year median value for Current Leases was $19.0 million (2024), whereas its average is $21.7 million.
  • Data for Intellia Therapeutics' Current Leases shows a peak YoY skyrocketed of 106.59% (in 2025) over the last 5 years.
  • Intellia Therapeutics' Current Leases (Quarterly) stood at $9.1 million in 2021, then surged by 83.11% to $16.7 million in 2022, then climbed by 11.47% to $18.6 million in 2023, then increased by 8.86% to $20.2 million in 2024, then spiked by 42.76% to $27.4 million in 2025.
  • Its Current Leases stands at $27.4 million for Q3 2025, versus $27.0 million for Q2 2025 and $38.8 million for Q1 2025.